This is a repository copy of *Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/98515/

Version: Supplemental Material

Table 1: Pain measured on a VAS – values used in model

Treatment	Change from baseline decrease for pain measured on a VAS: mean	Reference/ assumption
Adalimumab	29.00	[37]
Etanercept	5.48	[38]
Infliximab	5.48	Assumed same as etanercept
Rituximab	23.40	[39], [40], [41]
Abatacept	28.64	[42], [43], [44], [45], [46], [47]
Leflunomide	13.65	[48]
Gold	8.50	[49]
Cyclosporin A	10.15	[50]
Azathioprine	9.85	[51]
Palliative care	0.00	Assumed to have no effect

VAS: visual analogue scale